Display options
Cite
Manso L, Moreno F, Márquez R, et al. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015;22(2):e51-60doi: 10.3747/co.22.2210.
Manso, L., Moreno, F., Márquez, R., Castelo, B., Arcediano, A., Arroyo, M., Ballesteros, A. I., Calvo, I., Echarri, M. J., Enrech, S., Gómez, A., González Del Val, R., López-Miranda, E., Martín-Angulo, M., Martínez-Jañez, N., Olier, C., & Zamora, P. (2015). Use of bevacizumab as a first-line treatment for metastatic breast cancer. Current oncology (Toronto, Ont.), 22(2), e51-60. https://doi.org/10.3747/co.22.2210
Manso, L, et al. "Use of bevacizumab as a first-line treatment for metastatic breast cancer." Current oncology (Toronto, Ont.) vol. 22,2 (2015): e51-60. doi: https://doi.org/10.3747/co.22.2210
Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, Gómez A, González Del Val R, López-Miranda E, Martín-Angulo M, Martínez-Jañez N, Olier C, Zamora P. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015 Apr;22(2):e51-60. doi: 10.3747/co.22.2210. PMID: 25908921; PMCID: PMC4399624.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2015 Apr;22(2):e51-60. doi: 10.3747/co.22.2210.

Use of bevacizumab as a first-line treatment for metastatic breast cancer.

Current oncology (Toronto, Ont.)

L Manso, F Moreno, R Márquez, B Castelo, A Arcediano, M Arroyo, A I Ballesteros, I Calvo, M J Echarri, S Enrech, A Gómez, R González Del Val, E López-Miranda, M Martín-Angulo, N Martínez-Jañez, C Olier, P Zamora

Affiliations

  1. Hospital Universitario 12 de Octubre, Madrid, Spain.
  2. Hospital Universitario Clínico San Carlos, Madrid, Spain.
  3. MD Anderson Cancer Center, Madrid, Spain.
  4. Hospital Universitario La Paz, Madrid, Spain.
  5. Hospital General Universitario de Guadalajara, Guadalajara, Mexico.
  6. Hospital Príncipe de Asturias, Alcalá de Henares, Spain.
  7. Hospital de la Princesa, Madrid, Spain.
  8. Centro Integral Oncológico Clara Campal, Madrid, Spain.
  9. Hospital Universitario Severo Ochoa, Leganés, Spain.
  10. Hospital Universitario de Getafe, Getafe, Spain.
  11. Hospital Universitario de Salamanca, Salamanca, Spain.
  12. Hospital Gregorio Marañón, Madrid, Spain.
  13. Hospital Ramón y Cajal, Madrid, Spain.
  14. Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.

PMID: 25908921 PMCID: PMC4399624 DOI: 10.3747/co.22.2210

Abstract

OBJECTIVE: During clinical practice, it can be challenging, given the lack of response biomarkers, to identify the patients with metastatic breast cancer (mbca) who would benefit most from the addition of bevacizumab to first-line standard chemotherapy. The aim of the present review was to summarize the relevant scientific evidence and to discuss the experience of a group of experts in using bevacizumab to treat mbca.

METHODS: A panel of 17 Spanish oncology experts met to discuss the literature and their experience in the use of bevacizumab as first-line treatment for mbca. During the meeting, discussions focused on three main issues: the profile of the patients who could benefit most from bevacizumab, the optimal bevacizumab treatment duration, and the safety profile of bevacizumab.

RESULTS: The subset of mbca patients who would benefit the most from the addition of bevacizumab to first-line standard chemotherapy are those with clinically defined aggressive disease. Treatment with bevacizumab should be maintained until disease progression or the appearance of unacceptable toxicity. In the mbca setting, the toxicity profile of bevacizumab is well known and can be managed in clinical practice after adequate training.

CONCLUSIONS: This expert group recommends administering bevacizumab as first-line treatment in patients with clinically aggressive disease.

Keywords: Bevacizumab; clinical practice; metastatic breast cancer

References

  1. J Clin Oncol. 2012 Oct 1;30(28):3444-7 - PubMed
  2. J Clin Oncol. 2014 Oct 10;32(29):3307-29 - PubMed
  3. J Clin Oncol. 2010 Jul 10;28(20):3239-47 - PubMed
  4. J Clin Oncol. 2011 Feb 20;29(6):632-8 - PubMed
  5. Cancer. 2012 Jun 1;118(11):2780-6 - PubMed
  6. Breast Cancer Res Treat. 2013 Aug;140(3):463-73 - PubMed
  7. Ann Pharmacother. 2009 Mar;43(3):490-501 - PubMed
  8. Ann Oncol. 2011 Mar;22(3):595-602 - PubMed
  9. Eur Heart J. 2008 Feb;29(3):413-21 - PubMed
  10. Clin Cancer Res. 2008 Dec 1;14(23):7871-7 - PubMed
  11. BMC Cancer. 2012 Oct 19;12:482 - PubMed
  12. J Clin Oncol. 2011 Jun 20;29(18):e560-2 - PubMed
  13. Angiogenesis. 2014 Oct;17 (4):909-20 - PubMed
  14. Lancet Oncol. 2012 Jul;13(7):724-33 - PubMed
  15. J Clin Oncol. 2013 Mar 20;31(9):1219-30 - PubMed
  16. Clin Cancer Res. 2013 Mar 1;19(5):1281-9 - PubMed
  17. Br J Hosp Med (Lond). 2010 Dec;71(12):670-7 - PubMed
  18. Br J Cancer. 2013 Mar 19;108(5):1052-60 - PubMed
  19. Am J Health Syst Pharm. 2009 Jun 1;66(11):999-1013 - PubMed
  20. J Clin Oncol. 2013 May 10;31(14):1719-25 - PubMed
  21. N Engl J Med. 2007 Dec 27;357(26):2666-76 - PubMed
  22. Ann Oncol. 2012 May;23(5):1130-7 - PubMed
  23. Oncologist. 2013;18(3):273-80 - PubMed
  24. Ann Oncol. 2012 Jan;23(1):111-8 - PubMed
  25. Ann Plast Surg. 2009 Jun;62(6):707-9 - PubMed
  26. Br J Cancer. 2012 May 22;106(11):1718-21 - PubMed
  27. Clin Transl Oncol. 2013 Oct;15(10):810-7 - PubMed
  28. Breast Cancer Res Treat. 2011 Nov;130(1):133-43 - PubMed
  29. Br J Nurs. 2009 Apr 9-22;18(7):424-8 - PubMed
  30. Oncology. 2012;82(4):218-27 - PubMed
  31. Clin J Oncol Nurs. 2009 Oct;13(5):564-72 - PubMed
  32. Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9 - PubMed
  33. Anticancer Res. 2014 Jan;34(1):227-33 - PubMed
  34. J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9 - PubMed
  35. Breast. 2012 Jun;21(3):242-52 - PubMed
  36. J Clin Oncol. 2009 Oct 20;27(30):4966-72 - PubMed
  37. Lancet. 2012 Nov 24;380(9856):1840-50 - PubMed
  38. Lancet Oncol. 2013 Feb;14(2):125-33 - PubMed
  39. J Clin Oncol. 2011 Apr 1;29(10):1252-60 - PubMed

Publication Types